A list of key references for healthcare professionals.

The following are selected references from pivotal and key Novartis-sponsored or Novartis-funded clinical trials of omalizumab for the treatment of severe allergic asthma.

The links below will take you to non-Novartis websites.

 

Humbert M et al.
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Allergy 2005;60(3):309–316.
View

Humbert M et al.
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.

Eur Respir J 2018;51(5):1702523.
View

Kulus M et al.
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Curr Med Res Opin 2010;26(6):1285–1293.
View

XSA20-C027 July 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]